Algernon Pharmaceuticals Announces Launch of Rights Offering

Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023

Psyence Partners with iNGENū for Palliative Care Clinical Trial in Australia

Wesana Health Announces Sale of SANA-13 Assets to Lucy Scientific Discovery

Wellbeing Subsidiary KGK Science Applies for a Controlled Substances Dealers License and Receives Approval to Proceed with Buildout

Patent Application Published for PharmAla Biotech’s MDMA Analogs

Cybin Announces Streamlined Clinical Alignment

PharmaDrug Collaborates with PharmaTher for Development of DMT Transdermal Patch

Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor

Lobe Sciences Ltd. Announces Exclusive Collaboration with Quality Chemical Laboratories LLC

Nirvana Life Sciences Inc. announces agreement to acquire the licensed distributor of a Patented, WHO approved, herbal treatment for opiate addiction

Awakn Life Sciences Signs Its First Licensing Partnership Agreement in Europe

Numinus Expands Research Capabilities with new Phoenix Clinical Research Site

Wellbeing Provides Bi-Weekly Default Status Report

Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase

Psyched Wellness Announces Sales Partnership with Spacestation CPG